

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



BrainAurora Medical Technology Limited
脑动极光医疗科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 6681)

VOLUNTARY ANNOUNCEMENT
BECOMING A STRATEGIC PARTNER OF BEIJING FRONTIER
BRAIN-COMPUTER INTERFACE INSTITUTE TO JOINTLY ADVANCE
THE CLINICAL TRANSLATION OF KEY BRAIN-COMPUTER
INTERFACE TECHNOLOGIES

This announcement is made by BrainAurora Medical Technology Limited 脑动极光医疗科技有限公司 (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis for the purpose of keeping the investors informed of the latest update on the business developments of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that the Group has recently officially become a strategic partner of Beijing Frontier Brain-Computer Interface Institute (北京前沿脑机接口研究院). On March 27, 2026, Zhejiang BrainAurora Medical Technology Co., Ltd., a subsidiary of the Company, entered into a strategic cooperation agreement with Beijing Frontier Brain-Computer Interface Institute on-site.

1. INTRODUCTION TO THE PARTNER

1.1 Beijing Frontier Brain-Computer Interface Institute

Beijing Frontier Brain-Computer Interface Institute was officially established in March 2026 under the initiative of Xuanwu Hospital, Capital Medical University. The Institute focuses on breakthroughs in core technologies and clinical translation in the field of brain-computer interface (BCI), aiming to respond to the national strategic deployment for future-oriented industries and strengthening Beijing’s innovation-leading capabilities in the high-end medical equipment sector. The Institute will build six common enabling platforms covering neuroelectrophysiological data resources, intelligent algorithm development, device development and testing, pre-clinical validation, biological sample bank, as well as clinical validation and third-party evaluation, striving to become a domestically leading, world-class research, development and translation platform for BCI.

2. BACKGROUND OF THE COLLABORATION

2.1 BCI Technology Enters a New Phase of Full-Chain Translation

As the National 15th Five-Year Plan identifies BCI as a key area of development, alongside relevant initiatives set out in the 2026 Government Work Report, the BCI industry is entering a period of accelerated growth. Against this backdrop, the establishment of the Beijing Frontier Brain-Computer Interface Institute marks a new phase in China's BCI sector, characterized by systematic, full-chain translation driven by significant clinical needs. The Institute confronts the pressing demands of over 100 million patients with neurological disorders in China, striving to resolve the current structural imbalance whereby technological advancement outpaces real-world application.

2.2 An Inevitable Choice for Collaborative Innovation among Industry, Academia, Research and Medicine

Medical rehabilitation has been identified as a core application domain for the commercialization of BCI technology. Leveraging the premier clinical resources of Xuanwu Hospital, Capital Medical University, the development of an innovation ecosystem that integrates engineering with medical sciences and fosters collaboration between industry and academia represents a critical pathway for advancing the clinical translation of BCI technology and establishing a seamless chain from data acquisition to validation. As an established participant in China's cognitive impairment digital therapeutics market, the Group possesses deep expertise in the convergence of brain science and AI technologies. The collaboration with the Institute will effectively facilitate the clinical validation and industrial deployment of core technologies.

3. PRINCIPAL TERMS OF THE COOPERATION AGREEMENT

3.1 Cooperation Objectives

The Parties agree to jointly advance the research and development as well as clinical validation of key products in the field of BCI. The Group will work in collaboration with the Institute and other strategic partner enterprises to promote the joint development of key initiatives, including a multimodal neurological disease database, a neuroelectrophysiological large-scale model, and closed-loop neuromodulation BCI products, with the aim of establishing an innovation ecosystem that integrates engineering with medical sciences and fosters collaboration between industry and academia.

3.2 Key Aspects of Cooperation

(1) Joint Research and Development and Clinical Validation

Leveraging the six common enabling platforms established by the Institute, the Parties will engage in in-depth cooperation in areas including the development of a multimodal neurological disease database, the development of a neuroelectrophysiological large-scale model, and the clinical validation of relevant BCI products.

(2) *Establishment of a Full-Chain Innovation Ecosystem*

The Group will leverage its technological expertise and productization capabilities in the field of cognitive impairment digital therapeutics to create deep synergies with the Institute's research and clinical resources. Together, the Parties will jointly develop a comprehensive value chain spanning from data to algorithms and from validation to products, thereby accelerating the clinical translation process of BCI technology.

3.3 Division of Responsibilities

(1) *Responsibilities of the Group (BrainAurora) :*

- To leverage its technological advantages in digital therapeutics and AI to participate in the joint research and development of key initiatives, including the neuroelectrophysiological large-scale model.
- To advance the productization and application validation of relevant technologies in alignment with clinical needs.
- To collaborate with the Institute and clinical institutions in exploring innovative application models of BCI technology in the field of cognitive impairment diagnosis and treatment.

(2) *Responsibilities of the Partner (Beijing Frontier Brain-Computer Interface Institute) :*

- To provide cutting-edge scientific research support and clinical resources in the field of BCI.
- To organize and conduct clinical research and validation through Xuanwu Hospital and the multi-center network.
- To establish common technology platforms and provide infrastructure support for collaborative research and development, including data, algorithms and validation.

4. SIGNIFICANCE AND STRATEGIC VALUE OF THE COOPERATION

4.1 Deepening Integration of Industry, Academia, Research and Medicine to Facilitate Translation of Key Technologies

This cooperation represents a deep integration between the Group and a national-level scientific research platform as well as leading clinical institutions. Through synergies with the Institute and Xuanwu Hospital, the Group will further consolidate its technological foundation in the fields of brain science and cognitive impairment, thereby accelerating the translation of cutting-edge BCI technologies into clinical applications.

4.2 Enhancing Full-Chain Capabilities to Reinforce Industry Leadership

As a strategic partner of the Institute, the Group will deeply participate in the development of the multimodal database and the neuroelectrophysiological large-scale model. This involvement will enable the Group to establish full-chain capabilities spanning data resources, algorithmic models and product translation in the BCI and digital therapeutics sectors, thereby continuously strengthening and expanding its industry leadership.

4.3 Supporting National Strategy and Contributing to Industrial Innovation

This cooperation aligns with the national strategic deployment to foster future-oriented industries. Through close collaboration with the Institute, the Group will contribute its corporate efforts to advancing the high-quality development of China's BCI industry and enabling cutting-edge technologies to benefit a broad patient population.

5. OPINION OF THE BOARD OF DIRECTORS

The Board of Directors is of the view that this strategic cooperation is in line with the Group's long-term development strategy and will enable the Group to leverage premier clinical resources to further strengthen its technological expertise and product offerings in the fields of BCI and cognitive impairment. Through complementary advantages with the Institute, the Group is expected to further solidify its leading position in the industry and create long-term value for its shareholders.

This cooperation does not constitute a connected transaction or a notifiable transaction under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

By order of the Board
BrainAurora Medical Technology Limited
Mr. Tan Zheng
Chairman and Executive Director

Hong Kong, April 2, 2026

As of the date of this announcement, the Board comprises: (i) Mr. Tan Zheng as executive director; (ii) Mr. Li Sirui, Ms. Li Mingqiu and Mr. Deng Feng as non-executive directors; and (iii) Mr. Lam Yiu Por, Dr. Duan Tao and Mr. Tu Lei as independent non-executive directors.